Warm Autoimmune Hemolytic Anemia Comorbidity and COVID-19 Infection: A Case Report.

Apart from severe acute respiratory syndrome and cytokine dysregulation, novel coronavirus disease 2019 (COVID-19) infection has also been associated with a broad range of complications including septicemia, thrombosis, thrombocytopenia, Guillain--Barre, antiphospholipid syndrome, and multiple organ...

Descripción completa

Detalles Bibliográficos
Publicado en:Clinical Laboratory Science Vol. 37; no. 1; pp. 12 - 18
Autores principales: GOMEZ, ISRAEL, TURKEL, SARAH, NASR, PAYMAN
Formato: case study tables/charts Journal Article
Publicado: American Society for Clinical Laboratory Science Winter2024
Acceso en línea:Ver este registro en EBSCOhost
Descripción
Sumario:Apart from severe acute respiratory syndrome and cytokine dysregulation, novel coronavirus disease 2019 (COVID-19) infection has also been associated with a broad range of complications including septicemia, thrombosis, thrombocytopenia, Guillain--Barre, antiphospholipid syndrome, and multiple organ failure. Warm autoimmune hemolytic anemia (WAIHA) in its clinical presentation is similar to other forms of hemolytic anemias in which hemoglobin level is the most direct indicator of clinical severity of the hemolytic event. In this report, we describe the case of a 31-year-old male, previously diagnosed with idiopathic WAIHA, who goes on to suffer a severe flare following a COVID-19 infection. Prior to the COVID-19 infection, the patient was in a stable condition and was taking part in a clinical study for the treatment of WAIHA. In the case of this patient, the COVID-19 infection elicited a severe hemolytic episode, which required admission to the hospital and multiple units of blood transfusion. The patient's hematological recovery correlated with improvement from COVID-19 symptoms. The patient was stabilized with glucocorticoids and discharged after 2 weeks of hospitalization. The current case supports the role of COVID-19 infection as a comorbidity factor in WAIHA.